nodes	percent_of_prediction	percent_of_DWPC	metapath
Efavirenz—CYP1A2—Pentoxifylline—systemic scleroderma	0.118	0.222	CbGbCtD
Efavirenz—CYP1A2—Leflunomide—systemic scleroderma	0.113	0.212	CbGbCtD
Efavirenz—CYP2C9—Leflunomide—systemic scleroderma	0.102	0.191	CbGbCtD
Efavirenz—CYP2D6—Captopril—systemic scleroderma	0.0729	0.137	CbGbCtD
Efavirenz—CYP2C19—Prednisone—systemic scleroderma	0.0603	0.114	CbGbCtD
Efavirenz—CYP3A4—Mycophenolate mofetil—systemic scleroderma	0.0365	0.0687	CbGbCtD
Efavirenz—CYP3A4—Prednisone—systemic scleroderma	0.0292	0.0549	CbGbCtD
Efavirenz—CYP2C9—cardial valve—systemic scleroderma	0.00205	0.723	CbGeAlD
Efavirenz—Nausea—Mometasone—systemic scleroderma	0.000285	0.000612	CcSEcCtD
Efavirenz—Anorexia—Lisinopril—systemic scleroderma	0.000285	0.000611	CcSEcCtD
Efavirenz—Gastrointestinal pain—Leflunomide—systemic scleroderma	0.000284	0.00061	CcSEcCtD
Efavirenz—Ataxia—Methotrexate—systemic scleroderma	0.000284	0.000609	CcSEcCtD
Efavirenz—Pain—Mycophenolic acid—systemic scleroderma	0.000284	0.000609	CcSEcCtD
Efavirenz—Constipation—Mycophenolic acid—systemic scleroderma	0.000284	0.000609	CcSEcCtD
Efavirenz—Palpitations—Mycophenolate mofetil—systemic scleroderma	0.000283	0.000608	CcSEcCtD
Efavirenz—Loss of consciousness—Mycophenolate mofetil—systemic scleroderma	0.000282	0.000605	CcSEcCtD
Efavirenz—Hyperglycaemia—Prednisone—systemic scleroderma	0.000281	0.000604	CcSEcCtD
Efavirenz—Cough—Mycophenolate mofetil—systemic scleroderma	0.00028	0.000601	CcSEcCtD
Efavirenz—Dizziness—Captopril—systemic scleroderma	0.000279	0.000599	CcSEcCtD
Efavirenz—Convulsion—Mycophenolate mofetil—systemic scleroderma	0.000278	0.000596	CcSEcCtD
Efavirenz—Depression—Prednisone—systemic scleroderma	0.000277	0.000595	CcSEcCtD
Efavirenz—Hypertension—Mycophenolate mofetil—systemic scleroderma	0.000277	0.000594	CcSEcCtD
Efavirenz—Urticaria—Leflunomide—systemic scleroderma	0.000276	0.000593	CcSEcCtD
Efavirenz—Abdominal pain—Leflunomide—systemic scleroderma	0.000275	0.00059	CcSEcCtD
Efavirenz—Body temperature increased—Leflunomide—systemic scleroderma	0.000275	0.00059	CcSEcCtD
Efavirenz—Feeling abnormal—Mycophenolic acid—systemic scleroderma	0.000273	0.000587	CcSEcCtD
Efavirenz—Myalgia—Mycophenolate mofetil—systemic scleroderma	0.000273	0.000586	CcSEcCtD
Efavirenz—Arthralgia—Mycophenolate mofetil—systemic scleroderma	0.000273	0.000586	CcSEcCtD
Efavirenz—Chest pain—Mycophenolate mofetil—systemic scleroderma	0.000273	0.000586	CcSEcCtD
Efavirenz—Neuropathy peripheral—Prednisone—systemic scleroderma	0.000273	0.000585	CcSEcCtD
Efavirenz—Breast disorder—Methotrexate—systemic scleroderma	0.000273	0.000585	CcSEcCtD
Efavirenz—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	0.000272	0.000584	CcSEcCtD
Efavirenz—Anxiety—Mycophenolate mofetil—systemic scleroderma	0.000272	0.000584	CcSEcCtD
Efavirenz—Toxic epidermal necrolysis—Methotrexate—systemic scleroderma	0.000272	0.000583	CcSEcCtD
Efavirenz—Hypersensitivity—Azathioprine—systemic scleroderma	0.000271	0.000582	CcSEcCtD
Efavirenz—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	0.000271	0.000582	CcSEcCtD
Efavirenz—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	0.000271	0.000582	CcSEcCtD
Efavirenz—Insomnia—Lisinopril—systemic scleroderma	0.00027	0.00058	CcSEcCtD
Efavirenz—Discomfort—Mycophenolate mofetil—systemic scleroderma	0.00027	0.000579	CcSEcCtD
Efavirenz—Paraesthesia—Lisinopril—systemic scleroderma	0.000268	0.000576	CcSEcCtD
Efavirenz—Vomiting—Captopril—systemic scleroderma	0.000268	0.000576	CcSEcCtD
Efavirenz—Dry mouth—Mycophenolate mofetil—systemic scleroderma	0.000267	0.000573	CcSEcCtD
Efavirenz—Dyspnoea—Lisinopril—systemic scleroderma	0.000266	0.000572	CcSEcCtD
Efavirenz—Rash—Captopril—systemic scleroderma	0.000266	0.000571	CcSEcCtD
Efavirenz—Dermatitis—Captopril—systemic scleroderma	0.000266	0.00057	CcSEcCtD
Efavirenz—Somnolence—Lisinopril—systemic scleroderma	0.000265	0.00057	CcSEcCtD
Efavirenz—Headache—Captopril—systemic scleroderma	0.000264	0.000567	CcSEcCtD
Efavirenz—Confusional state—Mycophenolate mofetil—systemic scleroderma	0.000264	0.000566	CcSEcCtD
Efavirenz—Dyspepsia—Lisinopril—systemic scleroderma	0.000263	0.000564	CcSEcCtD
Efavirenz—Abdominal pain—Mycophenolic acid—systemic scleroderma	0.000262	0.000563	CcSEcCtD
Efavirenz—Body temperature increased—Mycophenolic acid—systemic scleroderma	0.000262	0.000563	CcSEcCtD
Efavirenz—Asthma—Methotrexate—systemic scleroderma	0.000261	0.00056	CcSEcCtD
Efavirenz—Decreased appetite—Lisinopril—systemic scleroderma	0.00026	0.000557	CcSEcCtD
Efavirenz—Gastrointestinal disorder—Lisinopril—systemic scleroderma	0.000258	0.000553	CcSEcCtD
Efavirenz—Fatigue—Lisinopril—systemic scleroderma	0.000257	0.000553	CcSEcCtD
Efavirenz—Shock—Mycophenolate mofetil—systemic scleroderma	0.000257	0.000553	CcSEcCtD
Efavirenz—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	0.000257	0.000551	CcSEcCtD
Efavirenz—Thrombocytopenia—Mycophenolate mofetil—systemic scleroderma	0.000256	0.00055	CcSEcCtD
Efavirenz—Hypersensitivity—Leflunomide—systemic scleroderma	0.000256	0.00055	CcSEcCtD
Efavirenz—Pancreatitis—Methotrexate—systemic scleroderma	0.000256	0.000549	CcSEcCtD
Efavirenz—Constipation—Lisinopril—systemic scleroderma	0.000255	0.000548	CcSEcCtD
Efavirenz—Pain—Lisinopril—systemic scleroderma	0.000255	0.000548	CcSEcCtD
Efavirenz—Tachycardia—Mycophenolate mofetil—systemic scleroderma	0.000255	0.000548	CcSEcCtD
Efavirenz—Skin disorder—Mycophenolate mofetil—systemic scleroderma	0.000254	0.000546	CcSEcCtD
Efavirenz—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	0.000253	0.000543	CcSEcCtD
Efavirenz—Diarrhoea—Azathioprine—systemic scleroderma	0.000252	0.000541	CcSEcCtD
Efavirenz—Nausea—Captopril—systemic scleroderma	0.00025	0.000538	CcSEcCtD
Efavirenz—Anorexia—Mycophenolate mofetil—systemic scleroderma	0.000249	0.000535	CcSEcCtD
Efavirenz—Asthenia—Leflunomide—systemic scleroderma	0.000249	0.000535	CcSEcCtD
Efavirenz—Hallucination—Prednisone—systemic scleroderma	0.000248	0.000533	CcSEcCtD
Efavirenz—Pancytopenia—Methotrexate—systemic scleroderma	0.000248	0.000531	CcSEcCtD
Efavirenz—Feeling abnormal—Lisinopril—systemic scleroderma	0.000246	0.000528	CcSEcCtD
Efavirenz—Pruritus—Leflunomide—systemic scleroderma	0.000246	0.000528	CcSEcCtD
Efavirenz—Connective tissue disorder—Prednisone—systemic scleroderma	0.000245	0.000527	CcSEcCtD
Efavirenz—Gastrointestinal pain—Lisinopril—systemic scleroderma	0.000244	0.000524	CcSEcCtD
Efavirenz—Dizziness—Azathioprine—systemic scleroderma	0.000243	0.000522	CcSEcCtD
Efavirenz—Upper respiratory tract infection—Methotrexate—systemic scleroderma	0.000242	0.00052	CcSEcCtD
Efavirenz—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	0.000238	0.000512	CcSEcCtD
Efavirenz—Photosensitivity reaction—Methotrexate—systemic scleroderma	0.000238	0.000511	CcSEcCtD
Efavirenz—Asthenia—Mycophenolic acid—systemic scleroderma	0.000238	0.000511	CcSEcCtD
Efavirenz—Diarrhoea—Leflunomide—systemic scleroderma	0.000238	0.00051	CcSEcCtD
Efavirenz—Urticaria—Lisinopril—systemic scleroderma	0.000237	0.000509	CcSEcCtD
Efavirenz—Insomnia—Mycophenolate mofetil—systemic scleroderma	0.000237	0.000508	CcSEcCtD
Efavirenz—Abdominal pain—Lisinopril—systemic scleroderma	0.000236	0.000507	CcSEcCtD
Efavirenz—Body temperature increased—Lisinopril—systemic scleroderma	0.000236	0.000507	CcSEcCtD
Efavirenz—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	0.000235	0.000504	CcSEcCtD
Efavirenz—Pruritus—Mycophenolic acid—systemic scleroderma	0.000235	0.000504	CcSEcCtD
Efavirenz—Vomiting—Azathioprine—systemic scleroderma	0.000234	0.000502	CcSEcCtD
Efavirenz—Pneumonia—Methotrexate—systemic scleroderma	0.000234	0.000502	CcSEcCtD
Efavirenz—Eye disorder—Prednisone—systemic scleroderma	0.000233	0.000501	CcSEcCtD
Efavirenz—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	0.000233	0.000501	CcSEcCtD
Efavirenz—Somnolence—Mycophenolate mofetil—systemic scleroderma	0.000233	0.000499	CcSEcCtD
Efavirenz—Infestation NOS—Methotrexate—systemic scleroderma	0.000232	0.000499	CcSEcCtD
Efavirenz—Infestation—Methotrexate—systemic scleroderma	0.000232	0.000499	CcSEcCtD
Efavirenz—Drowsiness—Methotrexate—systemic scleroderma	0.000232	0.000499	CcSEcCtD
Efavirenz—Rash—Azathioprine—systemic scleroderma	0.000232	0.000498	CcSEcCtD
Efavirenz—Dermatitis—Azathioprine—systemic scleroderma	0.000232	0.000498	CcSEcCtD
Efavirenz—Depression—Methotrexate—systemic scleroderma	0.000232	0.000497	CcSEcCtD
Efavirenz—Flushing—Prednisone—systemic scleroderma	0.000232	0.000497	CcSEcCtD
Efavirenz—Headache—Azathioprine—systemic scleroderma	0.000231	0.000495	CcSEcCtD
Efavirenz—Stevens-Johnson syndrome—Methotrexate—systemic scleroderma	0.00023	0.000495	CcSEcCtD
Efavirenz—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	0.00023	0.000494	CcSEcCtD
Efavirenz—Dizziness—Leflunomide—systemic scleroderma	0.00023	0.000493	CcSEcCtD
Efavirenz—Renal failure—Methotrexate—systemic scleroderma	0.000228	0.00049	CcSEcCtD
Efavirenz—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	0.000227	0.000488	CcSEcCtD
Efavirenz—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.000227	0.000487	CcSEcCtD
Efavirenz—Angiopathy—Prednisone—systemic scleroderma	0.000226	0.000486	CcSEcCtD
Efavirenz—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	0.000226	0.000485	CcSEcCtD
Efavirenz—Immune system disorder—Prednisone—systemic scleroderma	0.000225	0.000484	CcSEcCtD
Efavirenz—Pain—Mycophenolate mofetil—systemic scleroderma	0.000224	0.00048	CcSEcCtD
Efavirenz—Constipation—Mycophenolate mofetil—systemic scleroderma	0.000224	0.00048	CcSEcCtD
Efavirenz—Arrhythmia—Prednisone—systemic scleroderma	0.000223	0.000479	CcSEcCtD
Efavirenz—Sweating—Methotrexate—systemic scleroderma	0.000223	0.000478	CcSEcCtD
Efavirenz—Haematuria—Methotrexate—systemic scleroderma	0.000222	0.000476	CcSEcCtD
Efavirenz—Vomiting—Leflunomide—systemic scleroderma	0.000221	0.000474	CcSEcCtD
Efavirenz—Alopecia—Prednisone—systemic scleroderma	0.000221	0.000474	CcSEcCtD
Efavirenz—Hypersensitivity—Lisinopril—systemic scleroderma	0.00022	0.000472	CcSEcCtD
Efavirenz—Hepatobiliary disease—Methotrexate—systemic scleroderma	0.00022	0.000472	CcSEcCtD
Efavirenz—Dizziness—Mycophenolic acid—systemic scleroderma	0.000219	0.000471	CcSEcCtD
Efavirenz—Rash—Leflunomide—systemic scleroderma	0.000219	0.00047	CcSEcCtD
Efavirenz—Dermatitis—Leflunomide—systemic scleroderma	0.000219	0.00047	CcSEcCtD
Efavirenz—Nausea—Azathioprine—systemic scleroderma	0.000219	0.000469	CcSEcCtD
Efavirenz—Headache—Leflunomide—systemic scleroderma	0.000218	0.000467	CcSEcCtD
Efavirenz—Erythema—Prednisone—systemic scleroderma	0.000217	0.000467	CcSEcCtD
Efavirenz—Malnutrition—Prednisone—systemic scleroderma	0.000217	0.000467	CcSEcCtD
Efavirenz—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	0.000216	0.000463	CcSEcCtD
Efavirenz—Asthenia—Lisinopril—systemic scleroderma	0.000214	0.00046	CcSEcCtD
Efavirenz—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	0.000214	0.000459	CcSEcCtD
Efavirenz—Pruritus—Lisinopril—systemic scleroderma	0.000211	0.000454	CcSEcCtD
Efavirenz—Vomiting—Mycophenolic acid—systemic scleroderma	0.000211	0.000453	CcSEcCtD
Efavirenz—Rash—Mycophenolic acid—systemic scleroderma	0.000209	0.000449	CcSEcCtD
Efavirenz—Dermatitis—Mycophenolic acid—systemic scleroderma	0.000209	0.000448	CcSEcCtD
Efavirenz—Hepatitis—Methotrexate—systemic scleroderma	0.000209	0.000448	CcSEcCtD
Efavirenz—Urticaria—Mycophenolate mofetil—systemic scleroderma	0.000208	0.000446	CcSEcCtD
Efavirenz—Headache—Mycophenolic acid—systemic scleroderma	0.000208	0.000446	CcSEcCtD
Efavirenz—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	0.000207	0.000444	CcSEcCtD
Efavirenz—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	0.000207	0.000444	CcSEcCtD
Efavirenz—Nausea—Leflunomide—systemic scleroderma	0.000206	0.000443	CcSEcCtD
Efavirenz—Urinary tract disorder—Methotrexate—systemic scleroderma	0.000206	0.000442	CcSEcCtD
Efavirenz—Vision blurred—Prednisone—systemic scleroderma	0.000205	0.00044	CcSEcCtD
Efavirenz—Urethral disorder—Methotrexate—systemic scleroderma	0.000205	0.000439	CcSEcCtD
Efavirenz—Diarrhoea—Lisinopril—systemic scleroderma	0.000204	0.000439	CcSEcCtD
Efavirenz—Ill-defined disorder—Prednisone—systemic scleroderma	0.000202	0.000433	CcSEcCtD
Efavirenz—Visual impairment—Methotrexate—systemic scleroderma	0.000201	0.000432	CcSEcCtD
Efavirenz—Anaemia—Prednisone—systemic scleroderma	0.000201	0.000431	CcSEcCtD
Efavirenz—Agitation—Prednisone—systemic scleroderma	0.0002	0.000429	CcSEcCtD
Efavirenz—Angioedema—Prednisone—systemic scleroderma	0.000199	0.000426	CcSEcCtD
Efavirenz—Dizziness—Lisinopril—systemic scleroderma	0.000197	0.000424	CcSEcCtD
Efavirenz—Erythema multiforme—Methotrexate—systemic scleroderma	0.000197	0.000423	CcSEcCtD
Efavirenz—Nausea—Mycophenolic acid—systemic scleroderma	0.000197	0.000423	CcSEcCtD
Efavirenz—Malaise—Prednisone—systemic scleroderma	0.000196	0.000421	CcSEcCtD
Efavirenz—Vertigo—Prednisone—systemic scleroderma	0.000195	0.000419	CcSEcCtD
Efavirenz—Eye disorder—Methotrexate—systemic scleroderma	0.000195	0.000419	CcSEcCtD
Efavirenz—Syncope—Prednisone—systemic scleroderma	0.000195	0.000418	CcSEcCtD
Efavirenz—Tinnitus—Methotrexate—systemic scleroderma	0.000195	0.000418	CcSEcCtD
Efavirenz—Cardiac disorder—Methotrexate—systemic scleroderma	0.000194	0.000416	CcSEcCtD
Efavirenz—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	0.000193	0.000414	CcSEcCtD
Efavirenz—Loss of consciousness—Prednisone—systemic scleroderma	0.000191	0.00041	CcSEcCtD
Efavirenz—Vomiting—Lisinopril—systemic scleroderma	0.00019	0.000408	CcSEcCtD
Efavirenz—Angiopathy—Methotrexate—systemic scleroderma	0.000189	0.000406	CcSEcCtD
Efavirenz—Immune system disorder—Methotrexate—systemic scleroderma	0.000188	0.000405	CcSEcCtD
Efavirenz—Rash—Lisinopril—systemic scleroderma	0.000188	0.000404	CcSEcCtD
Efavirenz—Convulsion—Prednisone—systemic scleroderma	0.000188	0.000404	CcSEcCtD
Efavirenz—Dermatitis—Lisinopril—systemic scleroderma	0.000188	0.000404	CcSEcCtD
Efavirenz—Mediastinal disorder—Methotrexate—systemic scleroderma	0.000188	0.000404	CcSEcCtD
Efavirenz—Asthenia—Mycophenolate mofetil—systemic scleroderma	0.000188	0.000403	CcSEcCtD
Efavirenz—Hypertension—Prednisone—systemic scleroderma	0.000188	0.000403	CcSEcCtD
Efavirenz—Headache—Lisinopril—systemic scleroderma	0.000187	0.000402	CcSEcCtD
Efavirenz—Pruritus—Mycophenolate mofetil—systemic scleroderma	0.000185	0.000397	CcSEcCtD
Efavirenz—Arthralgia—Prednisone—systemic scleroderma	0.000185	0.000397	CcSEcCtD
Efavirenz—Myalgia—Prednisone—systemic scleroderma	0.000185	0.000397	CcSEcCtD
Efavirenz—Anxiety—Prednisone—systemic scleroderma	0.000184	0.000396	CcSEcCtD
Efavirenz—Alopecia—Methotrexate—systemic scleroderma	0.000184	0.000396	CcSEcCtD
Efavirenz—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	0.000184	0.000394	CcSEcCtD
Efavirenz—Discomfort—Prednisone—systemic scleroderma	0.000183	0.000392	CcSEcCtD
Efavirenz—Erythema—Methotrexate—systemic scleroderma	0.000182	0.00039	CcSEcCtD
Efavirenz—Malnutrition—Methotrexate—systemic scleroderma	0.000182	0.00039	CcSEcCtD
Efavirenz—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	0.000179	0.000384	CcSEcCtD
Efavirenz—Dysgeusia—Methotrexate—systemic scleroderma	0.000178	0.000382	CcSEcCtD
Efavirenz—Nausea—Lisinopril—systemic scleroderma	0.000177	0.000381	CcSEcCtD
Efavirenz—Back pain—Methotrexate—systemic scleroderma	0.000176	0.000377	CcSEcCtD
Efavirenz—Shock—Prednisone—systemic scleroderma	0.000174	0.000375	CcSEcCtD
Efavirenz—Nervous system disorder—Prednisone—systemic scleroderma	0.000174	0.000373	CcSEcCtD
Efavirenz—Tachycardia—Prednisone—systemic scleroderma	0.000173	0.000372	CcSEcCtD
Efavirenz—Dizziness—Mycophenolate mofetil—systemic scleroderma	0.000173	0.000371	CcSEcCtD
Efavirenz—Skin disorder—Prednisone—systemic scleroderma	0.000172	0.00037	CcSEcCtD
Efavirenz—Hyperhidrosis—Prednisone—systemic scleroderma	0.000171	0.000368	CcSEcCtD
Efavirenz—Vision blurred—Methotrexate—systemic scleroderma	0.000171	0.000367	CcSEcCtD
Efavirenz—Anorexia—Prednisone—systemic scleroderma	0.000169	0.000363	CcSEcCtD
Efavirenz—Ill-defined disorder—Methotrexate—systemic scleroderma	0.000169	0.000362	CcSEcCtD
Efavirenz—Anaemia—Methotrexate—systemic scleroderma	0.000168	0.00036	CcSEcCtD
Efavirenz—Vomiting—Mycophenolate mofetil—systemic scleroderma	0.000166	0.000357	CcSEcCtD
Efavirenz—Rash—Mycophenolate mofetil—systemic scleroderma	0.000165	0.000354	CcSEcCtD
Efavirenz—Dermatitis—Mycophenolate mofetil—systemic scleroderma	0.000165	0.000354	CcSEcCtD
Efavirenz—Headache—Mycophenolate mofetil—systemic scleroderma	0.000164	0.000352	CcSEcCtD
Efavirenz—Malaise—Methotrexate—systemic scleroderma	0.000164	0.000352	CcSEcCtD
Efavirenz—Vertigo—Methotrexate—systemic scleroderma	0.000163	0.00035	CcSEcCtD
Efavirenz—Musculoskeletal discomfort—Prednisone—systemic scleroderma	0.000162	0.000347	CcSEcCtD
Efavirenz—Insomnia—Prednisone—systemic scleroderma	0.00016	0.000344	CcSEcCtD
Efavirenz—Paraesthesia—Prednisone—systemic scleroderma	0.000159	0.000342	CcSEcCtD
Efavirenz—Cough—Methotrexate—systemic scleroderma	0.000158	0.00034	CcSEcCtD
Efavirenz—Convulsion—Methotrexate—systemic scleroderma	0.000157	0.000338	CcSEcCtD
Efavirenz—Dyspepsia—Prednisone—systemic scleroderma	0.000156	0.000335	CcSEcCtD
Efavirenz—Nausea—Mycophenolate mofetil—systemic scleroderma	0.000155	0.000334	CcSEcCtD
Efavirenz—Chest pain—Methotrexate—systemic scleroderma	0.000155	0.000332	CcSEcCtD
Efavirenz—Arthralgia—Methotrexate—systemic scleroderma	0.000155	0.000332	CcSEcCtD
Efavirenz—Myalgia—Methotrexate—systemic scleroderma	0.000155	0.000332	CcSEcCtD
Efavirenz—Decreased appetite—Prednisone—systemic scleroderma	0.000154	0.000331	CcSEcCtD
Efavirenz—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	0.000154	0.00033	CcSEcCtD
Efavirenz—Fatigue—Prednisone—systemic scleroderma	0.000153	0.000328	CcSEcCtD
Efavirenz—Discomfort—Methotrexate—systemic scleroderma	0.000153	0.000328	CcSEcCtD
Efavirenz—Constipation—Prednisone—systemic scleroderma	0.000152	0.000326	CcSEcCtD
Efavirenz—Confusional state—Methotrexate—systemic scleroderma	0.000149	0.000321	CcSEcCtD
Efavirenz—Feeling abnormal—Prednisone—systemic scleroderma	0.000146	0.000314	CcSEcCtD
Efavirenz—Nervous system disorder—Methotrexate—systemic scleroderma	0.000145	0.000312	CcSEcCtD
Efavirenz—Thrombocytopenia—Methotrexate—systemic scleroderma	0.000145	0.000312	CcSEcCtD
Efavirenz—Gastrointestinal pain—Prednisone—systemic scleroderma	0.000145	0.000311	CcSEcCtD
Efavirenz—Skin disorder—Methotrexate—systemic scleroderma	0.000144	0.000309	CcSEcCtD
Efavirenz—Hyperhidrosis—Methotrexate—systemic scleroderma	0.000143	0.000308	CcSEcCtD
Efavirenz—Anorexia—Methotrexate—systemic scleroderma	0.000141	0.000303	CcSEcCtD
Efavirenz—Urticaria—Prednisone—systemic scleroderma	0.000141	0.000302	CcSEcCtD
Efavirenz—Abdominal pain—Prednisone—systemic scleroderma	0.00014	0.000301	CcSEcCtD
Efavirenz—Body temperature increased—Prednisone—systemic scleroderma	0.00014	0.000301	CcSEcCtD
Efavirenz—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	0.000135	0.00029	CcSEcCtD
Efavirenz—Insomnia—Methotrexate—systemic scleroderma	0.000134	0.000288	CcSEcCtD
Efavirenz—Paraesthesia—Methotrexate—systemic scleroderma	0.000133	0.000286	CcSEcCtD
Efavirenz—Dyspnoea—Methotrexate—systemic scleroderma	0.000132	0.000284	CcSEcCtD
Efavirenz—Somnolence—Methotrexate—systemic scleroderma	0.000132	0.000283	CcSEcCtD
Efavirenz—Hypersensitivity—Prednisone—systemic scleroderma	0.000131	0.000281	CcSEcCtD
Efavirenz—Dyspepsia—Methotrexate—systemic scleroderma	0.00013	0.00028	CcSEcCtD
Efavirenz—Decreased appetite—Methotrexate—systemic scleroderma	0.000129	0.000277	CcSEcCtD
Efavirenz—Gastrointestinal disorder—Methotrexate—systemic scleroderma	0.000128	0.000275	CcSEcCtD
Efavirenz—Fatigue—Methotrexate—systemic scleroderma	0.000128	0.000274	CcSEcCtD
Efavirenz—Asthenia—Prednisone—systemic scleroderma	0.000127	0.000273	CcSEcCtD
Efavirenz—Pain—Methotrexate—systemic scleroderma	0.000127	0.000272	CcSEcCtD
Efavirenz—Pruritus—Prednisone—systemic scleroderma	0.000125	0.000269	CcSEcCtD
Efavirenz—Feeling abnormal—Methotrexate—systemic scleroderma	0.000122	0.000262	CcSEcCtD
Efavirenz—Diarrhoea—Prednisone—systemic scleroderma	0.000121	0.000261	CcSEcCtD
Efavirenz—Gastrointestinal pain—Methotrexate—systemic scleroderma	0.000121	0.00026	CcSEcCtD
Efavirenz—Urticaria—Methotrexate—systemic scleroderma	0.000118	0.000253	CcSEcCtD
Efavirenz—Dizziness—Prednisone—systemic scleroderma	0.000117	0.000252	CcSEcCtD
Efavirenz—Abdominal pain—Methotrexate—systemic scleroderma	0.000117	0.000252	CcSEcCtD
Efavirenz—Body temperature increased—Methotrexate—systemic scleroderma	0.000117	0.000252	CcSEcCtD
Efavirenz—CYP2C19—digestive system—systemic scleroderma	0.000115	0.0404	CbGeAlD
Efavirenz—Vomiting—Prednisone—systemic scleroderma	0.000113	0.000242	CcSEcCtD
Efavirenz—CYP2B6—skin of body—systemic scleroderma	0.000112	0.0395	CbGeAlD
Efavirenz—Rash—Prednisone—systemic scleroderma	0.000112	0.00024	CcSEcCtD
Efavirenz—Dermatitis—Prednisone—systemic scleroderma	0.000112	0.00024	CcSEcCtD
Efavirenz—Headache—Prednisone—systemic scleroderma	0.000111	0.000239	CcSEcCtD
Efavirenz—Hypersensitivity—Methotrexate—systemic scleroderma	0.000109	0.000234	CcSEcCtD
Efavirenz—Asthenia—Methotrexate—systemic scleroderma	0.000106	0.000228	CcSEcCtD
Efavirenz—Nausea—Prednisone—systemic scleroderma	0.000105	0.000226	CcSEcCtD
Efavirenz—Pruritus—Methotrexate—systemic scleroderma	0.000105	0.000225	CcSEcCtD
Efavirenz—Diarrhoea—Methotrexate—systemic scleroderma	0.000101	0.000218	CcSEcCtD
Efavirenz—Dizziness—Methotrexate—systemic scleroderma	9.8e-05	0.00021	CcSEcCtD
Efavirenz—Vomiting—Methotrexate—systemic scleroderma	9.42e-05	0.000202	CcSEcCtD
Efavirenz—CYP1A2—digestive system—systemic scleroderma	9.35e-05	0.033	CbGeAlD
Efavirenz—Rash—Methotrexate—systemic scleroderma	9.35e-05	0.000201	CcSEcCtD
Efavirenz—Dermatitis—Methotrexate—systemic scleroderma	9.34e-05	0.0002	CcSEcCtD
Efavirenz—Headache—Methotrexate—systemic scleroderma	9.29e-05	0.000199	CcSEcCtD
Efavirenz—CYP2B6—digestive system—systemic scleroderma	8.97e-05	0.0316	CbGeAlD
Efavirenz—CYP2C9—digestive system—systemic scleroderma	8.88e-05	0.0313	CbGeAlD
Efavirenz—Nausea—Methotrexate—systemic scleroderma	8.8e-05	0.000189	CcSEcCtD
Efavirenz—CYP1A2—lung—systemic scleroderma	7.81e-05	0.0275	CbGeAlD
Efavirenz—CYP2B6—lung—systemic scleroderma	7.49e-05	0.0264	CbGeAlD
Efavirenz—CYP3A4—digestive system—systemic scleroderma	6.77e-05	0.0239	CbGeAlD
Efavirenz—CYP2D6—digestive system—systemic scleroderma	6.66e-05	0.0235	CbGeAlD
